1. Home
  2. TCRX vs GEOS Comparison

TCRX vs GEOS Comparison

Compare TCRX & GEOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TCRX
  • GEOS
  • Stock Information
  • Founded
  • TCRX 2018
  • GEOS 1980
  • Country
  • TCRX United States
  • GEOS United States
  • Employees
  • TCRX N/A
  • GEOS N/A
  • Industry
  • TCRX Biotechnology: Pharmaceutical Preparations
  • GEOS Industrial Machinery/Components
  • Sector
  • TCRX Health Care
  • GEOS Industrials
  • Exchange
  • TCRX Nasdaq
  • GEOS Nasdaq
  • Market Cap
  • TCRX 82.1M
  • GEOS 72.9M
  • IPO Year
  • TCRX 2021
  • GEOS 1997
  • Fundamental
  • Price
  • TCRX $1.45
  • GEOS $13.91
  • Analyst Decision
  • TCRX Strong Buy
  • GEOS
  • Analyst Count
  • TCRX 6
  • GEOS 0
  • Target Price
  • TCRX $9.50
  • GEOS N/A
  • AVG Volume (30 Days)
  • TCRX 669.3K
  • GEOS 462.9K
  • Earning Date
  • TCRX 08-11-2025
  • GEOS 08-07-2025
  • Dividend Yield
  • TCRX N/A
  • GEOS N/A
  • EPS Growth
  • TCRX N/A
  • GEOS N/A
  • EPS
  • TCRX N/A
  • GEOS N/A
  • Revenue
  • TCRX $4,421,000.00
  • GEOS $116,542,000.00
  • Revenue This Year
  • TCRX $159.20
  • GEOS N/A
  • Revenue Next Year
  • TCRX N/A
  • GEOS N/A
  • P/E Ratio
  • TCRX N/A
  • GEOS N/A
  • Revenue Growth
  • TCRX N/A
  • GEOS N/A
  • 52 Week Low
  • TCRX $1.02
  • GEOS $5.51
  • 52 Week High
  • TCRX $7.89
  • GEOS $18.99
  • Technical
  • Relative Strength Index (RSI)
  • TCRX 46.44
  • GEOS 74.70
  • Support Level
  • TCRX $1.39
  • GEOS $15.31
  • Resistance Level
  • TCRX $1.73
  • GEOS $18.99
  • Average True Range (ATR)
  • TCRX 0.15
  • GEOS 1.44
  • MACD
  • TCRX -0.02
  • GEOS 0.96
  • Stochastic Oscillator
  • TCRX 12.53
  • GEOS 76.70

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

About GEOS Geospace Technologies Corporation (Texas)

Geospace Technologies Corp is engaged in designing and manufacturing seismic instruments and non-seismic equipment used in the oil and gas industry. The company has three different segments: oil and gas markets, adjacent markets, and emerging markets. The oil and gas markets segment, which accounts for the majority of the company's revenue, includes traditional exploration products, wireless exploration products, and reservoir characterization products and services. The adjacent markets business is closely tied to the oil and gas markets and includes imaging products and industrial products. The company operates globally across Asia, Canada, Europe, the United States, South America, Mexico, and other regions with a majority of its revenue being generated within the United States.

Share on Social Networks: